Background
Men who have sex with men (MSM) using HIV-pre-exposure prophylaxis (PrEP) show increased vulnerability to human papillomavirus (HPV)-related cancers. Despite this, comprehensive clinical guidelines for this population remain absent. Identifying specific risk factors is essential for sexual health centers to optimize care among MSM using PrEP. This study aims to collect HPV-related data in MSM on PrEP and use it to inform prevention guidelines for HPV and HIV in Europe.
Methods
This prospective cohort study includes participants from Germany and Austria. In the German cohort, there are 100 PrEP users and 100 PrEP-naive individuals, while in the Austrian cohort, there are 15 PrEP users and 15 PrEP-naive individuals. The total of 230 MSM are surveyed to compare sociodemographic factors, HPV vaccination status, and sexual histories. Participants undergo clinical examinations to detect HPV-associated pathologies and HPV genotyping by polymerase chain reaction (PCR) on anal, oral, and penile swabs.
Results
In the German cohort, anal swabs revealed high-risk (HR) HPV in 68% of PrEP users versus 34% of PrEP-naive individuals; intermediate-risk (IR) HPV in 29% vs. 8%, and low-risk (LR) HPV in 51% vs. 30%, respectively. Penile swabs indicated HR HPV in 18% of PrEP users and 10% of PrEP-naive participants; IR HPV in 3% for both; and LR HPV in 9% vs. 7%. Oral swabs showed low prevalence: HR HPV in 3% of PrEP users vs. 0% of PrEP-naive; IR HPV in 2% vs. 0%; and LR HPV in 3% vs. 1%. High-risk subtypes from anal swabs commonly found in cancers included HPV-16 in 18% of PrEP users vs. 10% of PrEP-naive, and HPV-18 in 11% vs. 6%. The median age in the PrEP using cohort was 39 compared to 30 in the PrEP naive cohort. Self-reported STIs were about twice as prevalent in the PrEP cohort. Dermatopathological conditions, including condyloma, were observed in both groups. Comparative analysis with Austrian data is ongoing.
Conclusions
The PrEP cohort showed significantly higher HPV prevalence, particularly anal and HR HPV subtypes 16 and 18, underscoring increased risk of HPV-related disease. When integrated with Austrian data, these findings will inform clinical recommendations and targeted prevention strategies to reduce HPV-related disease burden among PrEP-using MSM in Europe.